ReviewClinical and experimental medicine2025
From cardiac injury to omics signatures: a narrative review on biomarkers in septic cardiomyopathy.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of left ventricular ejection fraction and global longitudinal strain for short-term mortality in sepsis: a systematic review and meta-analysis.Journal of cardiothoracic surgery · 2026Pooled it
- The role of biomarkers across the care continuum in acute heart failure.Biomarker research · 2026Review
- Association of Baseline and Dynamic Changes in Growth Differentiation Factor-15 Changes with Longitudinal Myocardial Function in Sepsis.Journal of cardiovascular development and disease · 2026Article
- Sepsis-induced myocardial dysfunction: from mechanisms to precision critical care.Intensive care medicine experimental · 2026Article
- Septic Cardiomyopathy: Age-Dependent Physiology and Hemodynamic Aspects-A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Xiangdan Injection attenuates experimental sepsis-induced myocardial injury by suppressing inflammation and preserving mitochondrial ultrastructure.Frontiers in pharmacology · 2026Article
- Development and validation of a clinical prediction model for sepsis-induced cardiomyopathy.Frontiers in cardiovascular medicine · 2026Article
- Troponin I as a prognostic marker for outcomes in septic patients admitted to the ICU: Evidence from a government medical college of Madhya Pradesh, India.Bioinformation · 2026Article
- Xiangdan injection mitigates cardiac injury in experimental sepsis through inflammatory suppression and mitochondrial protection.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeptic cardiomyopathy (SCM) is a frequent and underdiagnosed complication of sepsis that contributes significantly to patient morbidity and mortality. Its pathophysiology involves myocardial inflammation, mitochondrial dysfunction, and microcirculatory abnormalities. Despite growing recognition, the diagnostic approach to SCM remains inconsistent, and validated biomarkers are lacking.
methodsThis narrative review explores the current landscape of SCM biomarkers. PubMed, Scopus, and EMBASE were searched from inception to June 2025.
resultsTraditional biomarkers are useful, but nonspecific in the septic context. Emerging biomarkers offer promising diagnostic and prognostic information, particularly in combination. Multi-omics strategies revealed transcriptomic and proteomic profiles to be potentially specific for SCM and may facilitate early detection and risk stratification. However, limitations remain in terms of standardization, assay reproducibility, and clinical translation. Composite biomarker panels and longitudinal monitoring appear to be more informative than single-point measurements.
conclusionsSCM remains a diagnostic challenge, although biomarker research is rapidly evolving. Integrating traditional and emerging biomarkers, supported by multi-omics and computational tools, may enable a shift toward precision medicine in sepsis-related cardiac dysfunction. Future efforts should focus on consensus definitions, validation in prospective cohorts, and biomarker-guided interventions to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.